ScionxBio uses its xRNA platform to engineer long-acting RNA medicines that combine multiple therapies in a single treatment, with an initial focus on cardiometabolic disease. By expanding RNA beyond nature's four-letter alphabet, xRNA uses position-specific chemical modifications to sustain protein expression for weeks to months rather than days, while lowering innate immune sensing for a cleaner safety profile.
At the heart of the platform is the TERÅ engine, a closed-loop system in which deep-learning design, proprietary combinatorial assembly, high-throughput screening, and continuous model retraining work together to optimise each molecule for its specific payload. Because the hardest chronic diseases rarely stem from a single cause, xRNA is built to deliver programmable combinations of payloads aimed at multiple independent disease drivers in a coordinated, finely tuned way.
Our initial focus is cardiometabolic disease — one of medicine's largest and fastest-growing areas — and the same long-acting, multi-pathway approach extends to other complex chronic conditions, turning transient treatments into durable therapies for chronic disease. A spinoff from Eleven Therapeutics, ScionxBio operates across Cambridge (UK), Tel Aviv, and Cambridge (MA).

ScionxBio

Org chart

Teams

Offices

ScionxBio

Org chart

Teams

Offices

Related companies